Community protocols on TRT describe: 1-2 mg subcutaneous daily (FDA-approved dose: 2 mg) 6-12 month protocols for visceral fat reduction Monitoring waist circumference, fasting glucose, and IGF-1 For men tracking their body composition changes on TRT, adding tesamorelin can accelerate the visceral fat reduction that typically takes 6-12 months on testosterone alone

For weight management , if a GLP-1 agonist was prescribed primarily for obesity, alternatives include: Orlistat , a lipase inhibitor that reduces fat absorption Structured lifestyle interventions including dietary modification, increased physical activity, and behavioural therapy Bariatric surgery for patients meeting NICE criteria (typically BMI 40 kg/m or 35 kg/m with obesity-related conditions) [2] Next steps following an allergic reaction should include: Documentation of the allergy in medical records and prescription systems Provision of written information about the reaction for the patient Discussion of alternative treatment options tailored to individual clinical needs Regular follow-up to monitor diabetes control and adjust therapy as needed Consideration of referral to specialist services (endocrinology, allergy, or weight management) where appropriate Reporting the suspected adverse reaction to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk) Patients should be reassured that effective alternatives exist and that an allergic reaction to one medication does not preclude successful management of their condition with other therapies

It activates G-protein coupled receptors FFAR2 and FFAR3 on L cells, triggering calcium influx and subsequent GLP-1 vesicle release
To this effect we tested the well-known calcium ionophore and previously described eryptosis inducer ionomycin ( Figures 3A, B )